Cost of Goods Sold Analysis for Manufacturing mRNA-Based Cell and Gene Therapies

This study utilizes a cost-of-goods-sold model to demonstrate that licensing and royalty fees are the primary drivers of manufacturing costs for mRNA-based cell and gene therapies, accounting for approximately 83% of total expenses and representing the most significant opportunity for policy-driven cost reduction.

The Gist

Imagine you are trying to bake a very special, life-saving cake. You have the recipe, the oven, the flour, and the eggs. You might think the cost of the cake is mostly about how much the flour and sugar cost, or how much you pay the baker to mix it all together.

But this paper reveals a surprising twist: The cost of the cake isn't about the ingredients or the baker at all. It's about the "permission slip" you have to pay to use the recipe.

Here is the breakdown of the study on mRNA-based cell and gene therapies, explained simply:

The Big Picture: The "Permission Tax"

The researchers built a detailed calculator (a spreadsheet model) to figure out exactly how much it costs to manufacture a dose of mRNA therapy (like a gene therapy or a vaccine) at a large factory scale.

They found that if you look at the total price tag to make one dose, about 83 cents of every dollar goes to licensing and royalty fees.

• The Analogy: Imagine you want to sell a car. You spend money on steel, tires, and the mechanic's time. But in this case, the car company has to pay the inventor of the wheel and the inventor of the engine a massive fee just for every single car they sell. That fee is so huge it swallows up almost all the other costs.

The Three Scenarios: A Rollercoaster Ride

The researchers tested three different "worlds" to see how the costs change:

1. The "Best Case" (The Dream): Everything goes perfectly. You get great deals on materials, and the patent holders charge very low fees. The cost to make a dose is only $3.68.
2. The "Base Case" (Reality): This is what they expect to happen in the real world. The cost comes out to $56.09 per dose.
3. The "Worst Case" (The Nightmare): Materials are expensive, and patent holders charge high fees. The cost skyrockets to $383.22 per dose.

The Takeaway: The difference between the cheapest and most expensive version is huge (over 100 times!). Why? Because the "permission fees" (licensing and royalties) can change wildly depending on who you are talking to and what the contract says.

Where Does the Money Actually Go?

If you strip away those massive permission fees, here is what is left to pay for the actual making of the medicine:

• The Ingredients (Materials): This is the biggest chunk of the real manufacturing cost (about 61%). Think of this as the special flour and sugar. The most expensive part is the "transcription" step, where the mRNA is actually written.
• The Disposables (Consumables): (About 34%). These are the single-use plastic bags, tubes, and filters used in the factory. Because these therapies are so delicate, factories can't reuse these tools; they have to throw them away after every batch.
• The Factory & Workers (Capital & Labor): Surprisingly, this is tiny (only about 5%). Because these factories are huge and automated, the cost of the building and the workers' wages is actually very small compared to the cost of the ingredients and the permission fees.

The "LNP" Problem

A specific part of the permission fees stands out: Lipid Nanoparticles (LNPs).

• The Analogy: Think of mRNA as a fragile message in a bottle. To get that message into a human cell, it needs a protective "ship" to carry it. That ship is the LNP.
• The study found that the fee to use the technology to build these "ships" accounts for nearly 86% of all the licensing fees. It's like having to pay a toll to every single bridge you cross, but the toll for one specific bridge is so high it costs more than the entire trip.

What Can Be Done? (According to the Paper)

The paper suggests that simply trying to make the factory faster or cheaper won't solve the high cost problem, because the "permission fees" are the main driver.

Instead, the authors suggest three levers to pull:

1. Fix the Rules: Governments or organizations need to change how these patent fees work. Maybe create a "shared library" of patents so companies don't have to pay so many individual tolls.
2. Make the Medicine Stronger: If scientists can make the therapy so powerful that you need a smaller dose (less "flour" and a smaller "ship"), you pay less in materials and less in fees (since some fees are based on the price of the final product).
3. Use Specialized Factories: Instead of every company building their own factory, they should hire specialized "contract factories" (CDMOs). This keeps the cost of buildings and workers low.

Summary

The paper concludes that while the actual physical cost to bake the "cake" (the medicine) is relatively low (around $56), the fees paid to the people who own the recipe are what make the final price so high. Until those fees are addressed, the gap between what it costs to make the therapy and what patients are charged will remain very wide.

Technical Summary

Technical Summary: Cost of Goods Sold Analysis for mRNA-Based Cell and Gene Therapies

Problem Statement
Cell and gene therapies (CGT), particularly those based on mRNA platforms, offer transformative potential for treating genetic disorders and cancer. However, high production costs remain a critical barrier to patient access and commercial viability. While list prices for approved CGT products often exceed $1 million per treatment, the specific structure of manufacturing costs—the Cost of Goods Sold (COGS)—remains opaque in public literature. Existing analyses are often process-specific, proprietary, or lack the granularity required to inform policy and pricing strategies for mRNA-based therapies at commercial scale. There is a need for a transparent model to quantify the direct costs of production and identify modifiable cost drivers.

Methodology
The authors developed a transparent, Excel-based COGS model to analyze manufacturing costs for two mRNA-based products: a prophylactic mRNA vaccine and a therapeutic mRNA gene therapy. The model was structured around the standard manufacturing workflow: plasmid linearization, in vitro transcription (IVT) and capping, formulation and encapsulation (including lipid nanoparticle, LNP, preparation), aseptic fill and finish, refrigeration/storage, and quality control.

Cost inputs were aggregated from three sources:

1. Vendor Pricing: Direct quotes and catalog prices for GMP-grade materials and enzymes.
2. Literature: Peer-reviewed articles and grey literature regarding manufacturing yields and material usage.
3. Expert Consultation: Input from CGT manufacturing specialists on process assumptions and licensing norms.

The analysis was conducted at a commercial scale, defined as a 15-liter continuous manufacturing batch with 43 batches per production run in a large facility (≥200 full-time equivalents). Six cost categories were modeled: materials, consumables, capital, labor, licensing fees, and royalty fees. Three scenarios (worst-case, base-case, and best-case) were constructed to capture parameter uncertainty. A tornado diagram sensitivity analysis was employed to identify the cost components with the greatest leverage for cost reduction.

Key Results
Under base-case assumptions, the estimated total COGS per production run for the therapeutic mRNA product is $16,825,597, resulting in a cost per dose of $56.09. The analysis revealed a wide sensitivity range, with costs per dose varying from $3.68 (best case) to $383.22 (worst case).

The most significant finding is the dominance of intellectual property costs:

• Licensing and Royalty Fees: Together, these account for approximately 83% of total base-case COGS ($13.96 million of the $16.83 million total). Licensing fees alone constitute 41.6% ($6.996 million), and royalty fees constitute 41.4% ($6.96 million).
• Non-Licensing Costs: Excluding fees, material costs represent the largest share (61% of non-licensing COGS), followed by consumables (34%), capital (4%), and labor (1%).
• Process Steps: When excluding licensing and royalties, the mRNA transcription and capping (IVT) step is the most material-intensive, accounting for 53.3% of non-licensing COGS. Within IVT, capping analogs are the single largest reagent cost.
• Sensitivity: The sensitivity analysis confirms that licensing and royalty assumptions are the primary source of uncertainty. The range between best and worst cases for these two categories combined is approximately $19.8 million, whereas the combined range for all other cost categories (materials, consumables, labor, capital) is only approximately $630,000.

Key Contributions
This study provides a granular, scenario-based breakdown of mRNA-based CGT manufacturing costs, moving beyond aggregate estimates to isolate specific cost drivers.

• Structural Insight: The paper identifies that the high cost of mRNA therapies is not primarily driven by physical production inputs (materials, labor, capital) but by the contractual structure of intellectual property. Licensing and royalty fees create a "structural cost floor" that is largely insensitive to manufacturing efficiency improvements or volume scale-up.
• Quantification of IP Impact: By quantifying that licensing and royalties consume roughly 83 cents of every dollar spent on production, the study highlights a specific area where policy intervention could yield the most significant cost reductions.
• Model Validation: The model was validated using publicly available data for an mRNA vaccine before being applied to the therapeutic mRNA use case, ensuring the structural integrity of the cost categories.

Significance and Claims
The authors assert that their findings have direct implications for both manufacturers and policymakers.

• For Policy: Because licensing and royalty fees are the dominant cost driver, government actions to support licensing reform, create shared intellectual property pools, or increase transparency in licensing markets could have a more substantial impact on reducing therapy costs than investments in manufacturing efficiency alone.
• For Manufacturers: Strategic priorities for cost reduction should focus on optimizing reagent utilization (specifically in the IVT step), increasing platform potency to reduce dosage requirements (which lowers both material and dosage-sensitive licensing fees), and expanding the use of Contract Development and Manufacturing Organizations (CDMOs) to minimize capital and labor costs.
• Limitations: The authors modestly note that the model is based on a specific production scenario (15L continuous batch) and relies on estimated licensing terms, which are often proprietary. Consequently, the results represent a structural analysis of cost drivers rather than a precise prediction of any single commercial product's final price. The study concludes that while manufacturing optimization is necessary, it is insufficient to address the primary cost barrier without addressing the underlying licensing and royalty structures.